Maple Rock Capital Partners Inc. Has $57.27 Million Holdings in Bausch + Lomb Co. (NYSE:BLCO)

Maple Rock Capital Partners Inc. cut its holdings in shares of Bausch + Lomb Co. (NYSE:BLCO - Free Report) by 12.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,171,053 shares of the company's stock after selling 446,495 shares during the quarter. Bausch + Lomb comprises approximately 1.7% of Maple Rock Capital Partners Inc.'s portfolio, making the stock its 9th biggest holding. Maple Rock Capital Partners Inc. owned approximately 0.90% of Bausch + Lomb worth $57,269,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Alberta Investment Management Corp raised its position in Bausch + Lomb by 36.0% in the fourth quarter. Alberta Investment Management Corp now owns 3,008,193 shares of the company's stock valued at $54,328,000 after purchasing an additional 796,400 shares during the period. Whitebox Advisors LLC lifted its position in Bausch + Lomb by 16.1% in the 4th quarter. Whitebox Advisors LLC now owns 1,443,101 shares of the company's stock valued at $26,062,000 after purchasing an additional 199,856 shares during the last quarter. Arrowstreet Capital Limited Partnership boosted its position in shares of Bausch + Lomb by 51.5% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,218,431 shares of the company's stock worth $21,996,000 after buying an additional 414,138 shares during the period. Price T Rowe Associates Inc. MD bought a new position in Bausch + Lomb in the 4th quarter worth approximately $14,122,000. Finally, Gabelli Funds LLC increased its position in Bausch + Lomb by 10.3% in the 4th quarter. Gabelli Funds LLC now owns 430,000 shares of the company's stock valued at $7,766,000 after acquiring an additional 40,000 shares during the period. Hedge funds and other institutional investors own 11.07% of the company's stock.

Bausch + Lomb Price Performance

NYSE BLCO traded down $0.13 during midday trading on Monday, hitting $11.37. The company had a trading volume of 1,638,654 shares, compared to its average volume of 650,535. The firm has a 50-day moving average price of $13.91 and a 200-day moving average price of $16.86. Bausch + Lomb Co. has a twelve month low of $10.45 and a twelve month high of $21.69. The company has a current ratio of 1.60, a quick ratio of 1.01 and a debt-to-equity ratio of 0.72. The company has a market capitalization of $4.02 billion, a PE ratio of -12.49, a P/E/G ratio of 0.85 and a beta of 0.58.

Bausch + Lomb (NYSE:BLCO - Get Free Report) last released its earnings results on Wednesday, April 30th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.03 by ($0.10). The business had revenue of $1.15 billion during the quarter, compared to the consensus estimate of $1.15 billion. Bausch + Lomb had a negative net margin of 6.62% and a positive return on equity of 3.35%. The business's revenue was up 3.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.07 EPS. As a group, analysts anticipate that Bausch + Lomb Co. will post 0.74 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. Bank of America reduced their price target on shares of Bausch + Lomb from $18.00 to $17.00 and set an "underperform" rating for the company in a research note on Thursday, February 20th. Evercore ISI lowered their price target on Bausch + Lomb from $19.00 to $15.50 and set an "outperform" rating on the stock in a research report on Thursday. Wells Fargo & Company cut their price target on shares of Bausch + Lomb from $15.00 to $12.00 and set an "equal weight" rating for the company in a report on Thursday. Needham & Company LLC restated a "hold" rating on shares of Bausch + Lomb in a research report on Thursday, April 24th. Finally, Stifel Nicolaus reduced their price objective on shares of Bausch + Lomb from $17.00 to $15.00 and set a "hold" rating for the company in a research note on Thursday, April 3rd. One research analyst has rated the stock with a sell rating, seven have given a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus target price of $16.14.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.